Aktuellt
SENASTE
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is recruiting the next patient cohort on the two active sites after securing the go-ahead from the DMC committee during the quarter. The future OPEX base will reflect the post-Q3 strategic decision to focus on the Tumorad development program with all available resources.
LÄS MER
